1,4-Naphthoquinones potently inhibiting P2X7 receptor activity
R X Faria1, F H Oliveira1, J P Salles1
1Laboratório de Toxoplasmose e outras protozooses, Instituto Oswaldo Cruz, Fiocruz, Brazil.
European Journal of Medicinal Chemistry
|November 15, 2017
Summary
Researchers explored 1,4-naphthoquinone derivatives as antagonists for the P2X7 receptor (P2X7R). Compounds AN-03 and AN-04 showed potent inhibition, suggesting their potential as novel anti-inflammatory drugs.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Molecular Biology
Background:
- The P2X7 receptor (P2X7R) is an ATP-gated ion channel implicated in inflammatory processes.
- Targeting P2X7R offers therapeutic potential for various inflammatory conditions.
Purpose of the Study:
- To synthesize and evaluate 1,4-naphthoquinone derivatives as P2X7R antagonists.
- To investigate the structure-activity relationships and binding modes of potent inhibitors.
- To assess the in vitro and in vivo efficacy of novel compounds against P2X7R activation.
Main Methods:
- Synthesis and biological screening of 1,4-naphthoquinone analogues.
- In vitro assays measuring dye uptake and IL-1β release.
- In vivo carrageenan-induced paw edema model.
- Electrophysiology and molecular docking for mechanism elucidation.
Main Results:
- Several 1,4-naphthoquinone derivatives exhibited significant antagonistic activity against human and murine P2X7R.
- Compounds AN-03 and AN-04 demonstrated superior potency compared to known blockers BBG and A740003.
- AN-03 and AN-04 effectively inhibited P2X7R-mediated dye uptake, IL-1β release, and paw edema in vivo.
Conclusions:
- 1,4-naphthoquinones, particularly AN-04, represent promising lead compounds for developing P2X7R blockers.
- These findings support the development of novel anti-inflammatory therapeutics targeting the P2X7 receptor.
Related Concept Videos
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.0K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.0K
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.8K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.8K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.1K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.1K
01:17Oxidation of Phenols to Quinones
4.9K
In the presence of oxidizing agents, phenols are oxidized to quinones. Quinones can be easily reduced back to phenols using mild reducing agents. The electron-donating hydroxyl group enhances the reactivity of the aromatic ring, enabling oxidation of the ring even in the absence of an α hydrogen.
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
4.9K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
655
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
655